ITM Reports Re-treatment and Dosimetry Data for 177Lu-Edotreotide
BOSTON, Mass. — September 27, 2026 ITM Isotope Technologies Munich SE and Lumara Bio announced new real-world re-treatment and...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
BOSTON, Mass. — September 27, 2026 ITM Isotope Technologies Munich SE and Lumara Bio announced new real-world re-treatment and...
